from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A monoclonal antibody used to treat squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, and glioma.


from Wiktionary, Creative Commons Attribution/Share-Alike License

-tu- +‎ -zu- +‎ -mab


  • YM's primary drug candidate is nimotuzumab, which is being tested against a variety of cancers including the brain cancer glioma, as well as cancers of the head and neck, pancreas, colon and lungs. - News

  • The company is making progress on its lead cancer drug nimotuzumab, which is in the same class as Erbitux (cetuximab), but has a better safety profile since it does not cause the severe (Grade 3 or 4) skin rash associated with these types of treatments. Home Page

  • During Fiscal 2011, YM's majority-owned joint venture, CIMYM BioSciences Inc. made a decision to focus its involvement with nimotuzumab on supporting the development and commercialization activities of its licensees, which have advanced the drug into late-stage clinical trials.

  • Japan, previously reported initiating a randomized Phase II trial with nimotuzumab in second line gastric cancer together with Kuhnil Pharma Co. Ltd., CIMYM's licensee in South Korea.

  • Increased development expenses for CYT387 and increases in salaries, travel and office expenses as a result of restructuring and the addition of the Australian office were offset by decreased expenses for nimotuzumab and termination of the AeroLEF® development program near the end of fiscal 2010.

  • Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab in

  • Following a management review of CIMYM's two randomized, Phase II, double-blind trials of nimotuzumab in patients with brain metastasis from non-small cell lung cancer NSCLC and for the palliative treatment of NSCLC, it decided in calendar Q2 2011 to close these studies to further enrollment due to slow rates of patient accrual and the projected timelines and costs anticipated to complete these studies.

  • Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that CYT387, nimotuzumab and CYT997 will generate positive efficacy and safety data in ongoing and future clinical trials, and that YM and its various partners will complete their respective clinical trials and disclose data within the timelines communicated in this release.

  • YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2 kinases; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a vascular disrupting agent VDA.

  • The decrease was due mainly to a three year extension of the amortization period for the up-front payment from Daiichi Sankyo related to the development of nimotuzumab.


Log in or sign up to get involved in the conversation. It's quick and easy.